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The incidence of the micro- and macrovascular complications of diabetes is rising, mirroring the increase in the worldwide
prevalence. Arguably, the most common microvascular complication is neuropathy, leading to deleterious changes in both the
structure and function of neurons. Amongst the various neuropathies with the highest symptom burden are those associated
with alterations in the enteric nervous system, referred to as diabetic enteropathy. The primary aim of this review is to provide a
contemporaneous summary of pathophysiology of diabetic enteropathy thereby allowing a “molecule to mechanism” approach
to treatment, which will include 4 distinct aspects. Firstly, the aim is to provide an overview of the diabetes-induced structural
remodelling, biochemical dysfunction, immune-mediated alterations, and inflammatory properties of the enteric nervous system
and associated structures. Secondly, the aim is to provide a synopsis of the clinical relevance of diabetic enteropathy. Thirdly,
the aim is to discuss the various patient-reported outcome measures and the objective modalities for evaluating dysmotility, and
finally, the aim is to outline the clinical management and different treatment options that are available. Given the burden of
disease that diabetic enteropathy causes, earlier recognition is needed allowing prompt investigation and intervention, which
may lead to improvements in quality of life for sufferers.
1. Introduction
The increasing incidence of both type 1 and type 2 diabetes
elevates the complications of diabetes as one of the most
important current public health issues [1], which causes neg-
ative impact on the individual quality of life and increased
socioeconomic expenditure. Amongst the diabetic complica-
tions with the highest symptom burden, yet frequently
underrecognised and suboptimally treated, are those associ-
ated with alterations in the enteric nervous system (ENS),
hereinafter referred to as diabetic enteropathy. This review
will focus on a “molecule to mechanism” approach of dia-
betic enteropathy and mechanism-based treatments.
2. The Enteric Nervous System
This review will provide a detailed summary of the remo-
delled and dysfunctional wall of the gastrointestinal (GI)
tract and the resulting pathological complications. These
include (1) reduced number of intrinsic enteric neurons, (2)
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structural neuronal changes, (3) intraneuronal biochemical
changes, (4) diminished secretion of neurotransmitters, (5)
altered immunomodulatory function of the enteric glial cells,
(6) neuroinflammation, and (7) altered gut-brain communi-
cation through spinal afferents and vagal terminals. These
concomitant changes cause altered GI motility and secretory
functions and explain—at least partly—the development and
maintenance of nausea/vomiting, bloating, early satiety,
diarrhoea, constipation, and abdominal pain.
The ENS consists of a complex network of neurons
and enteric glial cells (EGCs), which are embedded in
the wall of the GI tract. The neurons are localized in the
myenteric and submucosal plexi, which are connected by
interneurons. The myenteric plexus is situated between
the circular and longitudinal muscle layers and influences
GI motility. The submucosal plexus is in close proximity to
the muscularis mucosae, intrinsic vasculature, and the
mucosa [2] (Figure 1(a)) and regulates the secretion of
hormones and neurotransmitters. Furthermore, local sen-
sory neurons called intrinsic primary afferent neurons
(IPANs) regulate motility and maintain homeostasis. The
ENS is supplemented with extrinsic efferent input from the
central nervous system via autonomic (both sympathetic
and parasympathetic) pathways which also contribute to
the regulations and coordination of GI function [3].
Although the majority of enteric afferent axons are confined
to the gut wall, a large amount of sensory neurons from the
CNS following either vagal or spinal routes have receptive
fields in different layers of the GI wall and monitor GI
homeostasis [4]. Approximately 80–85% of the nerve fibres
in the vagus nerve are afferent and project viscerotopically
to the nucleus of the solitary tract [5].
Neurons of the ENS can be categorised according to their
connectivity and function (Figure 1(b)). The interstitial cells
of Cajal (ICCs), whilst not strictly neuronal, generate and
convey electrical impulses to smooth muscle cells facilitating
the slow wave peristaltic movement of the stomach and intes-
tines and are referred to as “pacemaker” cells [6].
In summary, the ENS comprises of three panenteric
juxtapositioned networks, namely, neurons, EGCs, and ICCs.
The detailed role of EGCs is discussed below; however,
both enteric neurons and EGCs are particularly vulnerable
to hyperglycaemia.
3. Diabetic Enteropathy
Diabetes significantly alters the microenvironment within
the ENS due to the effect of, amongst other hyperglycaemia,
oxidative stress, neuroinflammation, reduced levels of nerve
growth factors, and structural vascular changes [7–9]. In
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Figure 1: The enteric nervous system. (a) Cross-sectional view. The enteric nervous system (ENS) is embedded in the wall of the GI tract. The
neurons are localized in the myenteric and submucosal plexi and are connected by interneurons (depicted in grey). Extrinsic efferent
innervation via autonomic sympathetic (green) and parasympathetic (blue) pathways contributes to the regulation and coordination of GI
function. Extrinsic afferent sensory nerves (orange) following either vagal or spinal routes provide the central nervous system with
information about GI homeostasis. (b) Longitudinal view illustrating a selection of neuronal subtypes. Secretomotor and vasodilator
neurons regulate fluid and molecular exchange between gut lumen, tissue, and vasculature. Peristaltic movements (oral contraction and
aboral relaxation of intestinal smooth muscle) are facilitated by intrinsic primary afferent neurons (IPANs) activating ascending and
descending interneurons, which then activate upstream excitatory and downstream inhibitory motor neurons, respectively. IPANs may
initially be activated, e.g., through mechanoreceptors or by acetylcholine secreted by enteric endocrine cells in the luminal epithelial cell
layer upon luminal distension. In addition, ENS includes the innervation of gastroenteropancreatic endocrine cells (not shown) and gut-
associated lymphoid tissue, responsible for hormone secretion and transmitter release. Although not equally represented, the
juxtapositioned networks of enteric glial cells (EGCs) and interstitial cells of Cajal (ICCs) are present in all layers of the GI wall. Note that
the thickness of the different tissue layers is not proportionally represented.
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addition, other aspects such as increased levels of fatty acids,
miRNA, endothelia dysfunction or altered enteric microbiota
also have been proposed to exert an influence [10] although
these are outside the scope of this review.
3.1. Diabetes and Intracellular Biochemical Changes.Neurons
have continuously high glucose demand. They cannot allow
glycolytic and anaerobic episodes and are further provided
with a physiology that fails to regulate episodic glucose
uptake under the influence of insulin. Therefore, the neuro-
nal glucose uptake and utilization is highly dependent on the
extracellular glucose concentration and facilitated diffusion
mediated by primarily glucose transporter 3 (GLUT3); how-
ever, other forms including GLUT1, GLUT4, and GLUT8
are also present [11]. Hyperglycaemia in diabetes causes up
to fourfold increases in glucose levels, and if this is persistent
or repetitive, then intracellular glucose metabolism leads to
neuronal damage often referred to as glucose neurotoxicity
[12]. These mechanisms are primarily described in the
peripheral and central nervous systems, but the same mech-
anisms are present in the enteric nervous system.
The increased glucose flow through the glycolytic path-
way leads to increased levels of pyruvate, which is oxidised
in the citric acid cycle. This initiates a continuous elevated
flux of electron donors (NADH and FADH2) into the elec-
tron transport chain. Subsequently, this leads to an increased
voltage gradient across the inner mitochondrial membrane,
caused by the efflux of protons from the mitochondrial
matrix into the intermembrane lumen by complexes I, III,
and IV [13]. At a critical membrane potential threshold,
the electron transfer of complex III stalls [13], causing coen-
zyme Q to donate electrons to molecular oxygen, which gen-
erates superoxide, denoted O2
•− (Figure 2(a)). Superoxide is
a reactive oxygen species and drives the delirious effects of
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Figure 2: Hyperglycaemia induced intracellular biochemical changes in neurons. (a) Generation of ROS. (b) Consequences of ROS
generation. See text and Table 1 for explanation. Abbreviations: 1,3BPG: 1,3-bisphosphoglyceric acid; Acetyl-CoA: acetyl coenzyme A;
ADP: adenosine diphosphate; AGE: advanced glycation end products; ATP: adenosine triphosphate; DAG: diacylglycerol; DHAP;
dihydroxyacetone phosphate; e−: electron; F-1,6-BP: fructose-1,6-bisphosphate; F-6-P: fructose-6-phosphate; FAD: flavin adenine
dinucleotide (oxidised); FADH2: flavin adenine dinucleotide (reduced); GAP: glyceraldehyde 3-phosphate; GAPH: glyceraldehyde 3-
phosphate dehydrogenase; GlcN-6-P: glucosamine 6-phosphate; GR: glutathione reductase; GSH: glutathione; GSSG: glutathione
disulphide; H+: proton; NAD+: nicotinamide adenine dinucleotide (oxidised); NADH: nicotinamide adenine dinucleotide (reduced);
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oxygen: O2
•−: superoxide; P: phosphor group; PARP-1: poly(ADP-ribose) polymerase 1; PKC: protein kinase C; PP: diphosphate; RAGE:
receptor for advanced glycation end products; ROS: reactive oxygen species; UDP-GlcNAc: uridine diphosphate N-acetylglucosamine;
UTP: uracil triphosphate.
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increased intracellular glucose concentrations, which ulti-
mately leads to oxidative stress and tissue damage. Interest-
ingly, different populations of neurons have differing degrees
of susceptibility to glucose-initiated oxidative stress, which
results in pleomorphic neurological sequelae.
Animal models have shown that during hyperglycaemic
episodes, the extrinsic sympathetic supply, via coeliac and
superior mesenteric ganglia to the ENS, is more sensitive than
those deriving from the superior cervical ganglion [14]. Such
susceptibility has a number of consequences (Figure 2(b)).
Reactive oxygen species cause DNA double-strand breaks,
which in return activates DNA repair mechanisms, including
the enzyme PARP-1. Activated PARP-1 inhibits the key glyco-
lytic enzyme glyceraldehyde 3-phosphate dehydrogenase. This
causes the accumulation of upstream glycolytic intermediates
[15], which then are diverted into alternative and ultimately
pathogenic pathways (Table 1). Glycation of various intra-
and extracellular proteins and lipids ultimately results in the
formation of advanced glycation end products. Advanced gly-
cation end products activate receptor for advanced glycation
end products on the affected and surrounding cells, including
myeloid cells, initiating inflammatory and hence neurodegen-
erative signalling [16]. Depletion of intracellular NADPH ren-
ders the neuron susceptible to oxidative damage due to lacking
regeneration of the antioxidant glutathione, thereby resulting
in a “vicious” cycle.
Over time, the biochemical alterations coalesce with neu-
ronal structural changes and endothelial dysfunction to drive
the pathological development of diabetic neuropathy.
3.2. Diabetes and Enteric Neuroinflammation and Oxidative
Stress. Inflammation and oxidative stress are two synergistic
conditions, which have a significant negative impact on the
function of the ENS. In vitro studies of human EGCs have
demonstrated that inflammation induces proinflammatory
pathways leading to alterations in functional signalling path-
ways linked to GI motility such as mechanical-evoked Ca2+
and purinergic signalling [17], indicating that GI dysfunction
may indeed be related to inflammation. Whilst such findings
have not been comprehensively studied in clinical popula-
tions of diabetes, animal models have shown associations
between increased oxidative stress and gastroparesis, which
could be prevented by treatment with antioxidants [18]. Sim-
ilar observations have been made in the jejunal tissue of rats
with diabetes, where loss of both neurons and EGC was sig-
nificantly reduced after 120 days of supplement with the anti-
oxidant quercetin [19]. However, trials of antioxidants in
adults with diabetes have, to our knowledge, not yet been suc-
cessful in preventing or improving GI symptoms.
3.3. Diabetes and Structural Neuronal Changes. In animal
models of streptozotocin-induced diabetes (streptozotocin
is a drug that has preferential toxicity against pancreatic β
cells), there is marked degeneration, coupled with a reduction
in the density, of neurons in the myenteric plexus [20–24]. In
adults with diabetes, there is a reduction in the quantity of
colonic ENS, assessed as a total ganglion area by immunohis-
tochemical staining, in comparison to healthy controls [25].
Notably, autonomic neurons, including the ENS, are particu-
larly vulnerable to hyperglycaemia [26]. It has been suggested
that diabetes preferentially affects large fibre neurons in the
dorsal root ganglion and inhibitory neurons in the gut wall.
In particular, selective loss of nitric oxide synthase and neu-
ropeptide Y-expressing inhibitory neurons has been shown
in human diabetic colon [25]. However, since the overall
motility, coordination, and GI homeostasis are affected in
diabetes, it is plausible that IPANs are also vulnerable to
chronic hyperglycaemia. Moreover, degeneration and/or loss
of ICCs throughout the GI tract has been reported in both
animal models and in patients [18, 27], causing reduced
frequency of spontaneous muscular contractions. Finally,
smooth muscle myopathy [28] and angiopathy [8] are con-
sidered a contributing factor in the development of diabetic
enteropathy. Taken together, diabetes induces marked struc-
tural remodelling of the wall of the GI tract and its neuronal
support leading to altered function of the GI tract.
3.4. Diabetes and Immunomodulatory Involvement of Enteric
Glial Cells. Besides providing neurotrophic support, EGCs
mediate interactions between enteric neurons and other cell
types. Through a number of processes, they communicate
with immune effector cells, enteroendocrine cells, epithelial
cells, and blood vessels, forming a “circuit” that specialises
in the control and integration of bidirectional signals from
neurons to other cells [29]. Although EGCs exert immuno-
suppressive and anti-inflammatory effects protecting the
ENS against intraluminal foreign antigens, the physiological
role of each subtype is still incompletely understood [30].
For example, it has been shown that in diabetes, loss of
EGCs throughout the GI tract influences GI function
directly. Associated to this, a decreased secretion of neuro-
supportive factors has been observed [31]. For instance, glial
cell line-derived neurotrophic factor mediates differentiation
and migration of enteric neurons as well as survival and pro-
tection against the adverse effects of hyperglycaemia through
Table 1: Accumulation of upstream glycolytic intermediates and their consequences.
Glycolytic intermediate Alternative pathway Consequence
Glyceraldehyde-3-phosphate
(1) De novo synthesis of DAG
DAG activates protein kinase C resulting in altered
intracellular phosphorylation levels
(2) Glycosylation pathways
Glycation of various intra- and extracellular proteins and lipids∗
Fructose-6-phosphate (3) Hexosamine pathway
Glucose (4) Polyol pathway Leads to depletion of intracellular NADPH∗∗
∗ leads to formation of advanced glycation end products (AGE). ∗∗ renders the neuron susceptible to oxidation.
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the activation of the neuron-specific Ret tyrosine kinase
receptor and coupled PI3K and MAPK pathways in neurons
[31, 32]. Taken together, loss of EGC leads to neuronal
neglect and apoptosis in the diabetic ENS.
4. Clinical Aspects
As previously described, diabetes results in the loss of neu-
rons causing dysmotility and altered secretion within the
entire GI tract and therefore diabetic enteropathy should be
considered as a panenteric disorder. For example, oesopha-
geal motor disorders in persons with diabetes has a reported
prevalence of up to 63%, which is greater than that of gastro-
paresis (13%) [33]. A common secondary complication to
oesophageal motor disorders is gastroesophageal reflux dis-
ease. However, the most thoroughly described GI complica-
tion is gastroparesis, defined as delayed gastric emptying in
the absence of mechanical gastric outlet obstruction. It is esti-
mated that 5% of adults with type 1 diabetes and 1% of adults
with type 2 diabetes develop gastroparesis after 10 years of
disease duration [34]. The cardinal symptoms of gastropar-
esis are early satiety, postprandial fullness, bloating, nausea,
pain, vomiting, and weight loss [35]. However, there is con-
siderable interindividual variability in symptoms between
patients, with symptom severity being related to the duration
of diabetes [35] and poor glycaemic control [35, 36]. From a
mechanistic point of view, acute hyperglycaemia reduces the
rate of gastric emptying and increases the sense of fullness
during gastric distension directly [37, 38]. Changes in gastric
emptying lead to unpredictable delivery of nutrition (and
thus glucose) and oral pharmacotherapeutic agents into the
small bowel [39]. However, it is not known whether chronic
poor glycaemic control is the cause or the consequence of
gastroparesis, but in reality, it is likely that these factors inter-
act with one another. Notwithstanding the significant symp-
tom burden, gastroparesis is also associated with significant
healthcare expenditure. Notably, clinical examinations and
hospitalizations due to gastroparesis are increasing as well
as the length of stay [40].
The correlation between visceral neuropathy and GI
symptoms remains incompletely understood [41]. Lower
GI symptoms in adults with diabetes are common, with a
twofold increase in the risk of experiencing constipation,
diarrhoea, and faecal incontinence [34]. The prevalence
increases with poor glycaemic control, and both hard stools
and faecal incontinence are reported four times more often
in patients with poor diabetes regulation than in those who
are with well-regulated diabetes [34]. Several studies have
compared the prevalence of GI symptoms amongst adults
with diabetes types 1 and 2, but no consistent differences
have been found [35].
5. Patient-Reported Outcome Measures
Although patients’ experience and perceptions are central to
the clinical evaluation, patient-reported outcome measures/
questionnaires are helpful in both research and the longi-
tudinal monitoring of response to interventions. The most
commonly used are Patient Assessment of GI Disorders-
Symptom Severity Index (PAGI-SYM), Gastroparesis Car-
dinal Symptom Index (GCSI), Gastrointestinal Symptom
Rating Scale (GSRS), the Patient Assessment of Constipa-
tion Symptoms (PAC-SYM), and Patient Assessment of
Constipation-Quality of Life (PAC-QoL).
5.1. PAGI-SYM. PAGI-SYM assesses the severity of common
upper GI symptoms. This validated instrument contains 20
items and assesses six subscales: heartburn/regurgitation,
postprandial fullness/early satiety, nausea/vomiting, bloating,
upper abdominal pain, and lower abdominal pain. This ques-
tionnaire allows monitoring of outcomes in clinical practice
and trials and is a reliable instrument in subjects with gastro-
esophageal reflux disease, dyspepsia, or gastroparesis [42].
5.2. GCSI.GCSI consists of three subscales measuring nausea/
vomiting, postprandial fullness/early satiety, and bloating
derived from the PAGI-SYM. It is based on a 2-week recall,
has been validated, and is reliable in assessing symptom
severity related to gastroparesis [43]. Conflicting results have
been reported concerning the association between upper GI
symptoms, as measured by GCSI, in diabetes and objective
measures of gastroparesis, e.g., scintigraphic measures of
gastric emptying [44–46]. However, the recent study con-
firmed that the severity of early satiety and postprandial full-
ness are associated with prolonged gastric emptying [47]. To
evaluate the responsiveness to treatment of gastroparesis in
clinical trials, the Gastroparesis Cardinal Symptom Index-
Daily Diary (GCSIDD) was developed and validated.
5.3. GSRS. GSRS evaluates a wide range of GI symptoms. The
questionnaire contains 15 items which are combined into five
symptom clusters, namely, reflux, abdominal pain, indiges-
tion, diarrhoea, and constipation [48]. However, the link
between GSRS score and objective measures needs a further
study. In a clinical setting, the GSRS gives a broader perspec-
tive on patients’ panenteric GI symptoms in general, in com-
parison to the GCSI score, which focus on gastroparesis.
5.4. PAC-SYM and PAC-QoL. PAC-SYM and PAC-QoL
were developed to evaluate symptom severity and quality of
life in patients with constipation. The PAC-SYM is com-
posed of 12 items with three subscales: abdominal symptoms,
stool symptoms, and rectal symptoms. It is valid and reliable
in the assessment of the presence and severity of constipation
symptoms in adults over time as well as the ability to distin-
guish between responders and nonresponders to treatment
[49]. A modified version (M-PAC-SYM) excluding item 7
(rectal bleeding/tearing) has been developed for patients
with chronic constipation [49] and may be more relevant
for the evaluation of functional constipation in diabetes.
The PAC-QoL is a validated and consistent questionnaire
[50]. It includes 28 items forming four subscales (worries
and concerns, physical discomfort, psychosocial discomfort,
and satisfaction) and an overall scale, and thus, it is compre-
hensive in assessing the burden of constipation on patients’
well-being and everyday functioning. In diabetes, there is
an existing knowledge gap on the presence of prolonged
colonic transit and constipation and the potential implica-
tion on the experienced burden. Moreover, bioavailability
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of nutrition and on pharmacotherapeutic and glycaemic
control warrants further investigation [51].
6. Modalities for Assessing Motility
A number of modalities exist for objectively evaluating dia-
betic enteropathy. For detailed assessment of GI disorders,
objective investigations are a necessary supplement to subjec-
tive assessments. Although few has been strictly validated,
the most common tests are reviewed here.
6.1. Scintigraphy. Scintigraphic evaluation of gastric emp-
tying is considered to be the gold standard for investigat-
ing gastroparesis. This is a quantitative method in which
the patient ingests a 99-technicium-radiolabelled standard-
ized meal following which gastric emptying is measured.
Although widely available, differences in the delivery of the
test and its interpretation have limited the interpretation of
results between centres although significant efforts, e.g., from
the American Neurogastroenterology and Motility Society
and Society of Nuclear Medicine, have aided in the standard-
ization of the performance and interpretation of gastric emp-
tying [52]. Associations between scintigraphic results of
gastric emptying and clinical experienced symptoms are poor
but have been shown between gastric emptying and fullness/
early satiety and nausea/vomiting [53]. Scintigraphy can also
be used to measure small bowel transit time and colonic tran-
sit time although this requires prolonged sequential scanning
and is largely limited to a number of tertiary centres.
6.2. Breath Testing. Nonradioactive 13C isotope bound to a
digestible substance, most commonly octanoic acid, can be
used as a proxy of gastric emptying. 13C octanoic acid is
mixed with a solid meal and ingested, where it is absorbed
from the proximal small intestine. Subsequently, it is metab-
olized in the liver to 13C-CO2 and can be measured in exhaled
breath. Breath testing demonstrates good receiver operator
characteristics (sensitivity of 89% and specificity of 80%) in
comparison to scintigraphy [54]. In comparison to scintigra-
phy, 13C octanoic acid does not radiate and sampling can be
undertaken in the waiting room. However, concomitant
small bowel pathology, such as coeliac disease, can affect
breath testing results.
6.3. Manometry. Diabetes affects the oesophageal motility,
but studies show contradictive findings covering normal
oesophageal motility, delayed oesophageal transit times,
and reduced pressure of the lower oesophageal sphincter
[55]. However, most of these studies have used conventional
manometry catheters, which do not allow for continuous
pressure monitoring throughout the oesophagus. In con-
trast, a newer study in type 2 diabetes used high-resolution
oesophageal manometry and found that gastric emptying
and oesophageal motility were not generally altered, which
possibly suggests that the previous reported extent of gastro-
intestinal disorders in patients with diabetes may now be
reduced due to improved standards of care [56] and better
glycaemic control. Furthermore, high-resolution colonic
manometry has been used to evaluate physiology and patho-
physiology of constipation. Thus, the methodology has been
suggested to evaluate the gastrocolonic response, which is
potentially mediated by extrinsic neural pathways, and there-
fore, an absent response could indicate neuropathy in the
extrinsic colonic efferents [57, 58].
6.4. Wireless Motility Capsule. This system comprises of an
indigestible capsule that continuously measures pressure,
temperature, and pH as it traverses the GI tract. Based on ste-
reotypical changes in temperature and pH, segmental and
panenteric transit times can be derived [59]. The test involves
a standardized meal following which the patient ingests the
capsule; data is transmitted wirelessly to a receiver unit worn
by the patient until it is expelled. There are a set of robust
normal values, and its use has been approved by the Food
and Drug Administration [60]. In one study in patients
experiencing GI symptoms, 65% had prolonged gastric emp-
tying, 24% had prolonged small intestinal transit time, and
58% had prolonged colon transit time [61]. The findings mir-
rored another cohort of adults with diabetes and established
sensorimotor neuropathy, where 44% had abnormal transit
in one or more segments, independent of symptomatology
[51]. Therefore, accumulating evidence supports that gas-
troparesis can coexist with prolonged transit in the small
and large bowels as well as low contractility of the colon
[61–63]. Beyond pure measurement of transit times, it has
recently been proposed that the change in pH across the ileo-
caecal junction may represent a surrogate marker for caecal
fermentation, which itself may influence colonic transit times
[51]. Heightened bacterial fermentation in the caecum
increases the quantity of short-chain fatty acids, which
results in regional acidification. In the future, this may repre-
sent a potential therapeutic target in adults with diabetes. In
contrast to breath testing, the WMC method provides valu-
able knowledge such as orocaecal transit [64]; it is, however,
more expensive and limited to specialist centres.
6.5. Radiopaque Markers. Radiopaque markers (ROM) are
capsules containing plastic beads or rings that are ingested
by the patients following which a plain abdominal radio-
graph is undertaken. Although various protocols exist in
terms of the number of capsules to be taken and the number
of radiographs undertaken, it is a useful method to delineate
whole gut transit time and by proxy colonic transit time as
this is the major component of the former [65]. A gastric
emptying test with ROM is a widely available screening
method to detect delayed gastric emptying in adults with
diabetes, where a positive result seems reliable. However,
a normal ROM test does not exclude delayed gastric empty-
ing, and if the clinical suspicion of gastroparesis remains,
scintigraphy should be performed [53].
6.6. Emerging Techniques. Emerging techniques such as mag-
netic resonance imaging, the 3D transit system, and the video
capsule endoscopy are being developed to assess transit times
and motility [66]. Magnetic resonance imaging involves
repeated T2-weighted images being recorded by using non-
rigid image registration in regional areas of interest, and
small and large bowel motor function can be elucidated
[67]. The 3D transit system allows continuous tracking of
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an electromagnetic capsule ingested by a patient relative to an
external plate worn on the abdomen. In addition to transit
times, the system allows measurement of the speed, direction,
and duration of motility [68]. The video capsule endoscopy is
widely used clinically, for instance, to investigate occult
gastrointestinal bleeding [69]. Developments in automated
software analysis have allowed the systematic quantification
of the motion and dynamics of the small bowel [70]. How-
ever, whilst these novel techniques offer distinct advantages
over and above established methods, further work is needed
to define normative values as well as the relation of findings
to patient symptoms.
In summary, although most studies have focused on gas-
troparesis and GI symptoms in diabetes, newer studies show
panenteric multisegmental prolongation of transit times
prior to the development of clinical symptoms. Taken
together, associations between clinical symptoms and sen-
sory abnormalities of the GI tract show conflicting results,
which mirrors the neuronal complexity of the ENS, spinal
afferents, and central modulation. In the recent study, the
evaluation of the brain-gut axis was investigated in adults
with diabetes and GI symptoms. The authors provided evi-
dence for the interaction between autonomic neuropathy
and peripheral nervous degeneration, as well as changes in
the brain processing [71, 72]. Therefore, clinical GI symp-
toms may not originate from the GI tract but can be devel-
oped and maintained through altered central processing.
However, in the clinical setting, proactive encouragement of
patients to modify lifestyle factors such as improved glycae-
mic control, daily water intake, dietary aspects, and physical
exercise should be emphasized in order to minimise the
symptoms of diabetes-induced gut dysmotility.
7. Clinical Management
Diabetic enteropathy has no known cure. The goals of treat-
ment are therefore to slow the progression, relieve symptoms,
manage complications, and restore function. The key to
preventing or delaying neuropathy is primarily through tight
glycaemic control. Such targeted management guided by age,
disease duration, andoverall healthmay even improve current
symptoms. Dietary and lifestyle advice can give persons with
diabetes the tools for better control. Glycaemic control may
also improve by the usage of an insulin pump in persons with
insulin-dependent diabetes, or sometimes, the preprandial
insulin should be given after the meal or in reduced amount
when gastroparesis is present. Recently, continuous glucose
monitoring devices that allow for glucose readings in real
time have become available. Use of continuous glucose mon-
itoring is recommended by national and international medi-
cal organisations and expert clinician consensus both in
combination with pump and in persons on multiple daily
insulin injections [73–76]. Both insulin pump and continu-
ous glucose monitoring reduce the number of hyper- and
hypoglycaemic events and thus are believed to be neuropro-
tective. Beyond optimizing hyperglycaemic control, no avail-
able treatments address the underlying polyneuropathy.
The treatment of GI symptoms deriving from diabetic
enteropathy is challenging due to the multiple underlying
mechanisms. An overview of some of the most frequently
applied treatment possibilities is reviewed here.
7.1. Gastroparesis
7.1.1. Nonpharmacological Management. Initial treatment of
gastroparesis is based on dietary consulting and improve-
ment of glycaemic control. To enhance emptying of the
stomach, low soluble fibre, low fat, and small volume meals
are recommended with protein supplementation as needed
[77]. If standard dietary modifications are insufficient, small
particle size diet as well as liquid and homogenized nutri-
tional supplementations may be initiated with the reservation
of postpyloric enteral tube feeding for the most severe cases
[78]. Parenteral nutrition should be restricted to cases where
all other nutritional treatment modalities have failed.
7.1.2. Prokinetics. Prokinetics (Table 2) have been widely
studied in the context of diabetic gastroparesis and gener-
ally shown effect in most studies [77, 79, 80]. However, it
must be underlined that there is no absolute association
between symptom improvement and changes in gastric
motility after treatment with prokinetics [81] and most pro-
kinetic drugs are limited to short-term use due to the risk
of irreversible tardive dyskinesia (D2-receptor antagonists)
and currently subjected to black box warnings from the
FDA and EMA.
Future molecular targets to accelerate GI motility are cur-
rently identified, and relamorelin, a synthetic ghrelin analog,
has shown promising results, as it increases growth hormone
levels and accelerates gastric emptying [82]. Relamorelin has
proven to be superior to placebo for symptom relief in phase
IIA studies for diabetic gastroparesis, even though vomiting
frequency was not reduced. Until today, relamorelin has been
well tolerated and is safe in humans without cardiac or neu-
rologic adverse effects, yet it is not approved by the Food and
Drug Administration.
7.1.3. Tricyclic Antidepressants. In a retrospective study, low-
dose nortriptyline, amitriptyline, and desipramine have
shown to reduce symptoms in patients with diabetes, chronic
vomiting, and inadequate response to prokinetics [83]. How-
ever, in a large multicentre randomized controlled trial in
adults with idiopathic gastroparesis, the use of nortriptyline
(up to 75mg per day) compared with placebo for 15 weeks
did not improve the overall symptom score [84]. Thus, more
evidence is needed to make any conclusive recommendations
for diabetic gastroparesis.
7.1.4. Endoscopic Procedures. Most endoscopic procedures
evaluated for gastroparesis have been directed towards the
pylorus, to investigate whether pylorus spasms may contrib-
ute to symptoms and delayed gastric emptying. Intrapyloric
injection of botulinum toxin may transiently improve gastric
emptying in patients with gastroparesis (idiopathic and
diabetic), but after 1 month, the benefit was not superior to
placebo [85], and in patients with idiopathic gastroparesis,
botox was not superior to placebo in improving either symp-
toms or the rate of gastric emptying [86]. Other endoscopic
procedures include transpyloric stenting and endoscopic
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myomectomy of the pylorus, but at present, there are no
sufficient data to support these procedures outside protocol
settings [77].
7.1.5. Surgical Procedures. Gastric electrical stimulation
(GES) has been approved by the FDA as a Humanitarian
Device Exemption in patients with refractory symptoms of
diabetic or idiopathic gastroparesis [87]. It shows most
promising results in patients with predominance of nausea
and vomiting, where response rates up to 60% are shown in
uncontrolled studies. These results should, however, be inter-
preted cautiously because a controlled trial failed to show any
difference in symptom scores between the on and off
phases in patients treated for refractory diabetic gastropar-
esis [88]. The trial did, however, show a significant reduc-
tion in vomiting episodes during all phases compared with
the preimplantation period as well as favourable long-term
clinical outcome [89].
Other surgical options include total or subtotal gastrec-
tomy, which generally should be reserved as a last resort
treatment in patients with severe treatment refractory
symptoms after thorough evaluation in a multidisciplinary
setting. Importantly, the surgical reports reporting favour-
able outcomes of these procedures have all been performed
in uncontrolled settings, with relatively short follow-up.
Taken together, more studies are needed to elucidate the
underlying mechanisms and potentially identify the patients
that may benefit from surgical intervention.
7.2. Abnormal Bowel Function. The treatment options
available for bowel dysfunction in patients with diabetic
enteropathy follow the recommendations used for other
functional GI disorders.
7.2.1. Diarrhoea. In the presence of diarrhoea, patients
should be evaluated for secondary causes including infectious
and inflammatory bowel diseases, coeliac disease, exocrine
pancreatic insufficiency, and small bowel intestinal over-
growth [90]. Fibre supplementation might be helpful in some
cases but can also worsen symptoms of gastroparesis. In most
cases, loperamide is an effective and safe treatment for
chronic diarrhoea, although not formally evaluated in the
context of diabetic enteropathy [91].
7.2.2. Constipation. Treatment of constipation is based on
conventional laxatives that all have been shown to be rela-
tively efficient and safe [92]. In treatment of refractory cases,
a more detailed workup may be needed which ideally should
include assessment of intestinal transit time, endoscopy,
proctography, and anorectal-physiological evaluation. In
the presence of slow-transit constipation, osmotic laxatives
are preferred over fibre supplementation and bulking agents,
because they stimulate the intestines to absorb excessive
amounts of fluid from the body. Novel treatment options
include prucalopride [93] that may also improve symptoms
of gastroparesis, and linaclotide may be particularly helpful
in patients with concomitant symptoms of irritable bowel
syndrome [94]. Gastric symptoms in diabetes may be cau-
sed—at least in part—by vagal neuropathy, and therefore,
there is a theoretical background to use a neuromodula-
tion treatment option and this is the rationale for gastric
pacing. Several studies have shown that the method may
be effective to alleviate nausea and vomiting and is cost-
effective [95]. However, most studies have been small
and suffered from methodological problems (i.e., no sham
arm), and recent guidelines have not recommended this
modality outside protocol studies [96]. In idiopathic faecal
incontinence, emerging areas such as neuromodulation,
e.g., sacral nerve stimulation, have shown promising results
in other GI functional diseases [97]. Within diabetes enterop-
athy, data is sparse and currently, no randomized sham-
controlled studies exist, but such studies will undoubtedly
contribute with knowledge in the upcoming years.
7.3. Abdominal Pain. Treatment of abdominal pain sec-
ondary to diabetic enteropathy is complex and involves a
multidisciplinary approach including diabetologist, gastro-
enterologist, pain specialist, and psychologists. An active
Table 2: Prokinetic for treatment of diabetic gastroparesis.
Drug Mode of action
Recommended daily
dose (formulation)
Comment
Metoclopramide
5-HT4 receptor agonist
D2-receptor antagonist
10mg TID (tablet)
Black box warnings for long-term use:
(i) FDA< 3months
(ii) EMA≤ 5 days
Domperidone D2-receptor antagonist
10mg TID (tablet)
30mg BID (suppository)
Should be avoided in the presence of prolonged
QT interval
Erythromycin
Motillin receptor agonist
Cholinergic receptor agonist
250mg TID (tablet)
Clinical efficacy often diminishes after 2–4weeks
due to tachyphylaxia
Prokinetic action likely a drug class effect and other
macrolides with less toxicity may be used
(azithromycin, clarithromycin), but evidence from
controlled trials is lacking
Prucalopride 5-HT4 receptor agonist 2mg (tablet)
Currently under investigation for diabetic gastroparesis
in phase III trials. May be used off-label in selected cases
Granisetron 5-HT3 receptor agonist 3.1mg per 24 hours (patch)
Evidence from controlled trials is lacking in diabetic
gastroparesis
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screening for psychiatric comorbidity, including anxiety
and depression, should be done, and treatment initiated
if present. There is a paucity of studies investigating
pharmacological therapies for pain associated with diabetic
enteropathy. However, as the pain may be of neuropathic ori-
gin, drugs, which have been evaluated for this indication in
other diseases, may be helpful. These include antidepressants
(tricyclic antidepressants, selective serotonin reuptake inhib-
itors, and selective serotonin-noradrenaline reuptake inhibi-
tors) as well as the gabapentoids (gabapentin and pregabalin)
that can be used in combination depending on the clinical
situation [98]. However, in many patients, the pain is sec-
ondary to transit problems, bacterial overgrowth, and con-
stipation and shall be treated accordingly. Side effects to
medications can also give abdominal pain, and if patients
are treated with opioids on other indications, these may give
bowel dysfunction and abdominal pain [99].
8. Concluding Remarks
Symptoms from the GI tract, including dysmotility and
abdominal pain, are frequent in diabetes. Traditionally,
diabetes-induced gastrointestinal complications are focusing
solely on gastroparesis and symptoms of the upper gastroin-
testinal tract. However, accumulating evidence supports the
presence of structural and functional alterations in the ENS
of the entire GI tract and the interconnections with enteric
glial cells and interstitial cells of Cajal. This explains the bio-
chemical, immune-mediated, and inflammatory pathophysi-
ological mechanisms, which coalesce in the development and
maintenance of cell death, altered secretion of neurotrans-
mitters, dysmotility, and concomitant symptoms in the
entire length of the GI tract. Taken together, increased recog-
nition of diabetic enteropathy may allow earlier diagnosis
and intervention. This gives rise to hope for the recognition
of diabetic enteropathy at an earlier time and specific diagno-
ses in the future. Finally, more targeted nonpharmacological
and pharmacological treatments and interventions can be
individually tailored based on pathophysiological findings,
in order to improve patient outcomes.
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